« Back to Record
Citation APA

Schuler, M., Awada, A., Harter, P., Canon, J.-L., Possinger, K., Schmidt, M., De Greve, J., Neven, P., Dirix, L. Y., Jonat, W., Beckmann, M. W., Schütte, J., Fasching, P. A., Gottschalk, N., Besse-Hammer, T., Fleischer, F., Wind, S., Uttenreuther-Fischer, M., Piccart-Gebhart, M., & Harbeck, N. (2012). A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast cancer research and treatment, 134(3), 1149-1159. doi:10.1007/s10549-012-2126-1


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144331

Schuler, M., Awada, A., Harter, P., Canon, J.-L., Possinger, K., Schmidt, M., De Greve, J., Neven, P., Dirix, L. Y., Jonat, W., Beckmann, M. W., Schütte, J., Fasching, P. A., Gottschalk, N., Besse-Hammer, T., Fleischer, F., Wind, S., Uttenreuther-Fischer, M., Piccart-Gebhart, M., & Harbeck, N. (2012). A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast cancer research and treatment, 134(3), 1149-1159. doi:10.1007/s10549-012-2126-1